Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Determining the Safety of CAR T-Cell Therapy for Lymphoma

13 de novembro de 2026 atualizado por: University of Chicago

Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Visão geral do estudo

Descrição detalhada

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer.

Participants in this study will first have their T cells collected through a process called leukapheresis, where blood is drawn, spun through a machine to filter out T cells, and the remaining blood is returned to the body. In the laboratory, these T cells are modified with a Chimeric Antigen Receptor (CAR) protein, which acts like a targeting system to help the T cells recognize two specific markers on lymphoma cells: Cluster of Differentiation 19 (CD19) and Cluster of Differentiation 22 (CD22). The modified CAR T-cells are then given back to the participant through an intravenous (IV) infusion.

The main goal of this study is to find the safest and most effective dose of anti-CD19/CD22 CAR T-cells without causing unexpected or severe side effects. The study also evaluates how the body reacts to the treatment and measures how well the therapy works at shrinking or eliminating the cancer.

Tipo de estudo

Intervencional

Inscrição (Estimado)

36

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • The University of Chicago Medicine Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Alexandra E. Rojek, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
  • At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70
  • Measurable disease defined as ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
  • Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
  • Total bilirubin ≤ 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
  • Alanine aminotransferase (AST) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); or ≤ 5 x ULN if known lymphomatous infiltration of the liver
  • Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
  • Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiography, multigated acquisition scan (MUGA), or cardiac MRI
  • Baseline oxygen saturation ≥ 92% on room air
  • Adequate bone marrow function without growth factor support with short-acting G-CSF within the previous 7 days or long-acting G-CSF within the previous 14 days, and without transfusion support within 7 days prior to apheresis:
  • Absolute neutrophil count (ANC) ≥ 1,000/microliter (µL)
  • Absolute lymphocyte count (ALC) ≥ 100/microliter (µL)
  • Platelets ≥ 50,000/microliter (µL)
  • Hemoglobin ≥ 7g/dL
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from study enrollment:
  • Presence of acute or extensive chronic graft versus host disease (GVHD).
  • Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
  • History of another primary malignancy that has not been in remission for at least 2 years. The following are examples of exemptions from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou (PAP) smear, and in situ breast cancer that has been completely resected.
  • HIV seropositivity.
  • Subjects with uncontrolled intercurrent illness.
  • Pregnant or breastfeeding women are excluded from this study because CAR T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after protocol-directed CAR T-cell infusion are excluded (see Section 9.6 for contraception method). Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR T-cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
  • Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Presence of an active and clinically relevant CNS disorder such as epilepsy, generalized seizure disorders, paresis, aphasia, stroke, uncontrolled cerebrovascular disease, cerebellar disease, severe brain injuries, dementia and Parkinson's disease
  • History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
  • Patients who have received >1 prior CAR T-cell infusion. Patients treated with multiple CAR T-cell infusions in the context of a prior prospective therapeutic clinical trial will be permitted.
  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
  • History of severe immediate hypersensitivity reaction to tocilizumab, anakinra or any of the agents used in this study
  • Major surgery within 28 days prior to start of lymphodepleting chemotherapy or any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
  • Patients must have a washout period of at least 2 weeks or 5 half-lives, whichever is shorter, since any prior cancer therapy, at the time the patient undergoes apheresis, except as follows:
  • Treatment with alemtuzumab or bendamustine within 6 months of apheresis, or treatment with fludarabine, melphalan, or cladribine within 3 months of apheresis
  • Allogeneic hematopoietic stem cell transplant within 12 weeks prior to apheresis
  • Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 5 days prior to apheresis. Physiologic replacement, topical, and inhaled steroids are permitted.
  • Oral targeted agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to apheresis.
  • Experimental agents within 4 weeks of apheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to apheresis
  • Radiation within 6 weeks of apheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion or lesions, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both cluster of differentiation 19 (CD19) and cluster of differentiation 22 (CD22).
  • Prior bispecific T-cell engaging antibody therapy targeting cluster of differentiation 20 (CD20), cluster of differentiation 19 (CD19), or cluster of differentiation 22 (CD22) on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CD19-directed CAR T-cell infusion within 12 weeks of planned apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both CD19 and CD22.
  • Prior bispecific T-cell engaging antibody therapy targeting CD20, CD19, or CD22 on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CNS prophylaxis (e.g., intrathecal methotrexate): must be stopped at least 1 week prior to apheresis
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2 [IL-2]) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to apheresis.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose-Finding (Dose Escalation) Group

This group is part of the dose-finding phase of the study. The goal of this phase is to find the safest and most effective dose of CAR T-cell therapy with the fewest side effects.

Participants in this group will first receive lymphodepleting chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells. They will receive 1 of 4 dose levels of CAR T-Cells based on when they join the study and side effects to each dose level. Up to 18 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Outros nomes:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Outros nomes:
  • Fludara
  • fosfato de fludarabina

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Outros nomes:
  • Cytoxan
  • Neosar
Experimental: Dose Expansion Group

This group is part of the dose expansion phase of the study. The goal of this phase is to further test the dose of CAR T-cell therapy that was selected during the dose-finding phase.

Participants in this group will first receive chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells at the selected dose. Up to 36 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Outros nomes:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Outros nomes:
  • Fludara
  • fosfato de fludarabina

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Outros nomes:
  • Cytoxan
  • Neosar

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safe Dose Level (Recommended Phase 2 Dose)
Prazo: Day 30 after CAR T-cell infusion

To find the safest dose of anti-CD19/22 CAR T-cells as assessed by tracking severe side effects (dose-limiting toxicities) during the first month after treatment.

Day 30 after CAR T-cell infusion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Safety Profile of Anti-CD19/CD22 CAR T-cells
Prazo: First day of CAR T-cell infusion (Day 0) through 12 months after infusion

To describe the safety profile related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-cell infusion (Day 0) through 12 months after infusion
Severity of Toxicities Related to Treatment with Anti-CD19/CD22 CAR T-cells
Prazo: First day of CAR T-Cell infusion (Day 0) through 12 months after infusion

To record the severity of toxicities (side effects) related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
Percentage of Participants with Overall Response Rate
Prazo: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants whose cancer shrinks or completely disappears (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
Percentage of Participants with Complete Response Rate
Prazo: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants who show a complete disappearance of all signs of cancer (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Alexandra E. Rojek, MD, University of Chicago

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

13 de julho de 2027

Conclusão Primária (Estimado)

29 de outubro de 2031

Conclusão do estudo (Estimado)

29 de outubro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

13 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever